Your safety comes first

Tirzepatide Important Safety InformationPlease read before you begin.

This information is here to help you make an informed, confident decision together with your licensed provider. It does not replace a conversation with your provider about your own health history.

Having a medical emergency?

Call 911 or go to the nearest emergency room right away. For non-urgent questions about your treatment, message your care team.

01

Indication

Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Please review carefully
02

Contraindications

Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It should also not be used in patients with a history of severe gastrointestinal disease, including gastroparesis.

03

Warnings and Precautions

Risk of Thyroid C-Cell Tumors

GLP-1 receptor agonists, including tirzepatide, have been associated with a potential risk of thyroid C-cell tumors. Patients should be evaluated for relevant risk factors before starting treatment and monitored for symptoms such as a neck mass, hoarseness, trouble swallowing, or shortness of breath.

Pancreatitis

Acute pancreatitis, including serious cases, has been reported with GLP-1 receptor agonists. Patients should be informed of symptoms such as severe abdominal pain that may radiate to the back, with or without vomiting, and advised to discontinue use and seek immediate medical attention if these symptoms occur.

Hypoglycemia with Insulin or Insulin Secretagogues

The risk of hypoglycemia may increase when tirzepatide is used together with insulin or insulin secretagogues. Dose adjustments of those medications may be necessary.

Acute Kidney Injury

Cases of acute kidney injury and worsening renal function have been reported with GLP-1 receptor agonists, particularly in patients experiencing nausea, vomiting, diarrhea, or dehydration. Renal function should be monitored when appropriate.

Hypersensitivity Reactions

Serious allergic reactions, including anaphylaxis, angioedema, and urticaria, have been reported. If a hypersensitivity reaction occurs, tirzepatide should be discontinued and appropriate medical treatment should be initiated.

Gastrointestinal Adverse Reactions

Common gastrointestinal side effects may include nausea, vomiting, diarrhea, abdominal discomfort, and constipation. These symptoms are often more noticeable when starting treatment or increasing the dose and may lessen over time.

04

Most Common Adverse Reactions

  • Nausea
  • Vomiting
  • Diarrhea
  • Abdominal pain
  • Constipation
05

Pregnancy and Lactation

Tirzepatide should not be used during pregnancy unless specifically recommended by a licensed healthcare provider. It is not known whether tirzepatide passes into human milk. Patients who are pregnant, planning to become pregnant, or breastfeeding should discuss treatment options with their provider.

06

Drug Interactions

Caution should be used when tirzepatide is taken with medications that affect gastrointestinal motility or absorption, as well as medications that may increase the risk of hypoglycemia.

07

Patient Counseling Information

Patients should be counseled on the potential risks and benefits of tirzepatide therapy, including gastrointestinal side effects, hypoglycemia risk, and the importance of following provider instructions, diet, and exercise recommendations. Patients should also be educated on the signs and symptoms of thyroid tumors, pancreatitis, and serious allergic reactions.

08

Important Information

This medication is compounded by a licensed pharmacy in accordance with Section 503A of the Federal Food, Drug & Cosmetic Act and may be dispensed only pursuant to a patient-specific prescription issued by a licensed practitioner following a medical evaluation.

The FDA does not review or approve compounded medications, including compounded tirzepatide, for safety, effectiveness, or quality. Compounded tirzepatide has not been approved by the FDA for weight loss. Some third-party research suggests potential benefits, but individual results may vary.

This compounded formulation of tirzepatide is not affiliated with, endorsed by, or approved by Eli Lilly and is not intended to replace any FDA-approved product manufactured by Eli Lilly.

Actual product packaging may vary from images shown.

Disclaimer

Compounded medications are prepared to meet the needs of an individual patient based on a prescription from a licensed practitioner. They are not FDA-approved, and patients should discuss potential risks and benefits with their healthcare provider. 

*Most dosing levels are included within one simple program price. In some cases, higher dosing tiers may have higher costs, though many patients do not reach that stage.